Medtronic PLC (MDT)vsMaxCyte Inc (MXCT)
MDT
Medtronic PLC
$76.15
-2.32%
HEALTHCARE · Cap: $100.09B
MXCT
MaxCyte Inc
$0.84
-3.24%
HEALTHCARE · Cap: $90.34M
Smart Verdict
WallStSmart Research — data-driven comparison
Medtronic PLC generates 107343% more annual revenue ($35.48B vs $33.03M). MDT leads profitability with a 13.0% profit margin vs -135.1%. MDT earns a higher WallStSmart Score of 58/100 (C).
MDT
Buy58
out of 100
Grade: C
MXCT
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+27.7%
Fair Value
$107.79
Current Price
$76.15
$31.64 discount
Margin of Safety
+44.7%
Fair Value
$1.32
Current Price
$0.84
$0.48 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 20.0%
Generating 2.3B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Earnings declined 11.8%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -23.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MDT
The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin. PEG of 1.36 suggests the stock is reasonably priced for its growth.
Bull Case : MXCT
The strongest argument for MXCT centers on Price/Book, Debt/Equity.
Bear Case : MDT
The primary concerns for MDT are EPS Growth.
Bear Case : MXCT
The primary concerns for MXCT are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
MDT profiles as a value stock while MXCT is a turnaround play — different risk/reward profiles.
MXCT carries more volatility with a beta of 1.57 — expect wider price swings.
MDT is growing revenue faster at 8.7% — sustainability is the question.
MDT generates stronger free cash flow (2.3B), providing more financial flexibility.
Bottom Line
MDT scores higher overall (58/100 vs 30/100). MXCT offers better value entry with a 44.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Medtronic PLC
HEALTHCARE · MEDICAL DEVICES · USA
Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.
MaxCyte Inc
HEALTHCARE · MEDICAL DEVICES · USA
MaxCyte Inc. (MXCT) is a pioneering company in the field of cell-engineering, distinguished by its innovative Flow Electroporation® technology, which facilitates the efficient and scalable introduction of nucleic acids and proteins into various cell types. Serving a diverse clientele that includes leading biopharmaceutical companies and prominent research institutions, MaxCyte is strategically positioned in the burgeoning cell and gene therapy market. The company's cutting-edge platforms are integral to the development of novel cell-based therapies and vaccines, allowing it to seize substantial growth opportunities within the healthcare landscape. Committed to advancing transformative medical solutions, MaxCyte is set to meet the increasing global demand for innovative therapeutic approaches.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?